Adipotide

Adipotide is a targeted peptidomimetic designed to home to the vasculature that supports white adipose tissue and induce apoptosis there, effectively starving adipose tissue of blood supply. It is one of the more unusual anti-obesity development programs because it targets tissue vasculature rather than classic appetite or incretin pathways.

The compound has also been described as Prohibitin-TP01 and as a white-fat targeting peptidomimetic built from a homing motif linked to a pro-apoptotic sequence. Synonym management is important because the program appears in literature under both mechanistic and sponsor-style names.

Adipotide binds a prohibitin-associated target on blood vessels serving white adipose tissue, then delivers a pro-apoptotic payload that selectively damages that vasculature. The intended downstream effect is loss of white fat mass with accompanying improvement in insulin-resistance phenotypes.

Developed for obesity and obesity-linked metabolic dysfunction. In a research repository it also serves as a category-defining example of adipose-vasculature targeting therapy.

Public ADME detail is limited in open sources, but the biologic concept depends on tissue targeting more than systemic endocrine signaling. Nonhuman-primate work and early trial materials suggest parenteral administration rather than convenient oral use.

A notable 2011 study in obese Old World monkeys reported rapid weight loss, reduction in white adipose tissue, and improvement in insulin resistance. Those data made adipotide a high-interest translational obesity program, although the evidence base remains small and has not produced an approved therapy.

Renal effects are the major caution signal in the preclinical literature. The monkey study described predictable and reversible kidney changes at optimized doses, which is useful but not sufficient to establish a clinically acceptable safety window in humans.

Clinical-development materials describe injectable administration in an early-phase study setting. No approved regimen exists.

The following dosing information has been compiled from community forums, researcher discussions, and gray-market sources. This information has NOT been verified through peer-reviewed scientific studies or clinical trials. It does NOT constitute medical advice, a prescription, or a recommendation for human use.

This data is presented solely for informational and educational purposes to document what is commonly discussed in research communities. Dosing protocols may be inaccurate, dangerous, or based on anecdotal reports with no scientific validation. Individual responses vary significantly, and unregulated compounds carry inherent risks including contamination, mislabeling, and unknown side effects.

Always consult qualified medical professionals before making any health-related decisions. The repository maintainers assume no liability for the use or misuse of this information.

Researcher-Reported Dosing Protocols

Common Dose Range: 0.1-0.43 mg/kg

Administration Route: Subcutaneous injection

Frequency: Once daily

Timing: Morning, at a consistent time each day, with or without food.

Schedule / Protocol: 4-6 week cycles

Dose Escalation: It is commonly recommended to start with a lower dose of 0.1 mg/kg for the first 1-2 weeks to assess tolerance. The dose can be gradually increased if well-tolerated and if fat loss has plateaued, with close monitoring of kidney function.

Additional Notes: Adipotide is an experimental peptide and not approved for human use. The primary safety concern is dose-dependent and reversible kidney effects. Researchers emphasize the importance of close kidney function monitoring and adequate hydration throughout the administration period. The information provided is based on primate studies, as no human clinical trials have been conducted.

This researcher-reported dosing information was compiled from unverified community sources and does not represent validated scientific or medical guidance.

ClinicalTrials.gov records a first-in-man Phase I obesity study of Prohibitin-TP01 / adipotide. This establishes that the program entered human testing, but the public evidence trail does not support approved-use conclusions.

Investigational only; not FDA approved. Publicly visible development does not appear to have progressed into a marketed obesity therapy.

Because adipotide is a targeted peptidomimetic rather than a simple native hormone analog, manufacturing control would need to track peptide identity, linker integrity, purity, and stability carefully. Open-source CMC detail remains sparse.

Relevant comparators include AOD9604, GLP-1 / GIP / glucagon co-agonists, and other body-composition agents, though adipotide is mechanistically distinct because it attacks adipose vasculature rather than appetite signaling or lipolysis pathways.

Version 0.1 starter entry created March 14, 2026. Evidence basis for this draft: nonhuman-primate efficacy paper, ClinicalTrials.gov Phase I record, and sponsor-era public disclosures.